Compare CLIR & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLIR | CELU |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | 123 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 35.2M |
| IPO Year | 2011 | N/A |
| Metric | CLIR | CELU |
|---|---|---|
| Price | $4.81 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $6.00 |
| AVG Volume (30 Days) | 12.7K | ★ 112.8K |
| Earning Date | 04-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,000.00 | N/A |
| Revenue This Year | $34.29 | N/A |
| Revenue Next Year | $67.31 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $0.71 |
| 52 Week High | $7.56 | $4.35 |
| Indicator | CLIR | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 42.23 |
| Support Level | $4.18 | $0.71 |
| Resistance Level | $5.56 | $1.44 |
| Average True Range (ATR) | 0.41 | 0.06 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 46.01 | 64.72 |
ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.